Insights
Search Results
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Crosspoint Capital Partners on TENEX.AI’s $250 Million Series B
On March 31, 2026, TENEX.AI, the AI SOC company transforming security operations, announced a $250 million Series B round of financing led by Crosspoint Capital Partners. Wilson Sonsini Goodrich & Rosati advised Crosspoint on the transaction.
The proceeds from the Series B will accelerate TENEX.AI’s global expansion and significantly scale the human expertise behind its AI-native managed detection and response (MDR) service, expanding the team of defenders and engineers delivering cybersecurity outcomes. The TENEX.AI platform enables AI-driven triage, investigation, hunting, and response to threats in under a minute—with 100 percent alert coverage and human analysts governing every decision and accountable for every outcome.
The Wilson Sonsini team that advised Crosspoint on the financing included:
Corporate
Becki DeGraw
Travis Scheft
Michael Murrietta
Enid Qin
The proceeds from the Series B will accelerate TENEX.AI’s global expansion and significantly scale the human expertise behind its AI-native managed detection and response (MDR) service, expanding the team of defenders and engineers delivering cybersecurity outcomes. The TENEX.AI platform enables AI-driven triage, investigation, hunting, and response to threats in under a minute—with 100 percent alert coverage and human analysts governing every decision and accountable for every outcome.
The Wilson Sonsini team that advised Crosspoint on the financing included:
Corporate
Becki DeGraw
Travis Scheft
Michael Murrietta
Enid Qin
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
1.13.26
Wilson Sonsini Advises Proxima on $80 Million Seed Financing
On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.
Client Highlights
12.17.25
Wilson Sonsini Advises Udemy on Combination with Coursera
On December 17, 2025, Udemy, Inc., an AI-powered skills acceleration platform that combines on-demand, multi-language content with real-time innovation, and Coursera, Inc., an AI-powered online learning platform, announced that they have entered into a definitive merger agreement under which Coursera will combine with Udemy in an all-stock transaction. Based on the closing prices of Coursera and Udemy common stock on December 16, 2025, the implied equity value of the combined company is approximately $2.5 billion. The transaction is expected to close by the second half of 2026, subject to the receipt of required regulatory approvals, approval by Coursera and Udemy shareholders, and the satisfaction of other customary closing conditions.
Client Highlights
10.21.25
Wilson Sonsini Advises Armada Acquisition Corp. II on $1 Billion Business Combination with Evernorth Holdings
On October 20, 2025, Armada Acquisition Corp II (Armada II), a publicly traded special purpose acquisition company, and Evernorth Holdings Inc. (Evernorth), a newly formed Nevada corporation focused on enabling institutional-scale adoption of XRP, announced that they have entered into a definitive business combination agreement through which Evernorth will become a publicly listed company. The transaction is expected to raise more than $1 billion in gross proceeds, establishing Evernorth as the largest public XRP-treasury company and a first-of-its-kind institutional vehicle built to accelerate XRP adoption. Investors include SBI, Ripple, Rippleworks, and leading digital-asset and fintech investors such as Pantera Capital, Kraken, and GSR, with participation from Ripple co-founder Chris Larsen. Upon closing, the combined company will operate under the Evernorth name and is expected to trade on Nasdaq under the ticker symbol “XRPN,” subject to applicable listing requirements and other customary closing conditions.
Client Highlights
10.07.25
Wilson Sonsini Advises Viaduct on Acquisition by Sumitomo Rubber Industries
On October 1, 2025, Sumitomo Rubber Industries (SRI), one of the world’s largest tire companies and a global leader in mobility innovation, closed its acquisition of Viaduct, a pioneer in artificial intelligence (AI) solutions. Wilson Sonsini Goodrich & Rosati advised Viaduct on the transaction.
Client Highlights
8.19.25
Firm Advises Jolt Software on Acquisition by Digi International
On August 18, 2025, Digi International Inc., a leading global provider of business and mission-critical Internet of Things (IoT) products, services, and solutions, announced its acquisition of Jolt Software, Inc., a leading solutions provider to the convenience store and food and beverage industries. Wilson Sonsini Goodrich & Rosati advised Jolt Software on the transaction.
The acquisition marks a significant milestone for Digi’s SmartSense® business in advancing operational intelligence and compliance automation across foodservice, grocery, convenience, healthcare, and other verticals. It supports Digi’s strategy to expand annual recurring revenues (ARR) through high-value, scalable subscription offerings. Jolt will be integrated into SmartSense and will report results as part of the IoT Solutions segment.
The Wilson Sonsini team that advised Jolt on the transaction included:
The acquisition marks a significant milestone for Digi’s SmartSense® business in advancing operational intelligence and compliance automation across foodservice, grocery, convenience, healthcare, and other verticals. It supports Digi’s strategy to expand annual recurring revenues (ARR) through high-value, scalable subscription offerings. Jolt will be integrated into SmartSense and will report results as part of the IoT Solutions segment.
The Wilson Sonsini team that advised Jolt on the transaction included:
Client Highlights
7.25.25
Wilson Sonsini Advises Revival on Strategic Partnership with Olympus
On July 25, 2025, Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships in MedTech, announced a strategic partnership with Olympus Corporation (Olympus), a global healthcare leader committed to making people’s lives healthier, safer, and more fulfilling through advanced medical technologies and solutions. The partnership is aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal (GI) treatments. Wilson Sonsini Goodrich & Rosati advised Revival on the transaction and on fund matters related to the transaction.
Client Highlights
7.22.25
Wilson Sonsini Advises dYdX on its Acquisition of Pocket Protector
On July 18, 2025, dYdX, a decentralized derivatives exchange, announced its recent acquisition of Pocket Protector, a crypto social trading platform. The acquisition includes Pocket Protector’s products joining the dYdX product suite and brings Pocket Protector’s engineering team to dYdX. With this recent addition, dYdX plans to expand into new forms of trading and integrate social features into its core products. Wilson Sonsini Goodrich & Rosati advised dYdX on the transaction.